This week I finished the most recent book in my self-guided study of 20th century technology, namely The Idea Factory: Bell Labs and the Great Age of American Innovation, by Jon Gertner. As the title implies, it’s a chronicle of research and development wing of AT&T, a history that lasts.
Brain inflammation appears to influence the mood problems of Alzheimer's patients, rather than traditional markers of the disease like amyloid beta or tau proteins, researchers report.
File it further under: Issues that May Resolve Themselves.
But for now, it s a question without an obvious answer: If the Red Sox rotation stays healthy and effective, who gets bumped to the bullpen when ace left-hander Chris Sale returns from Tommy John surgery in the second half?
Before the season, throw a dart would ve been an acceptable response, because expectations were low. We knew the rotation would improve upon the unwatchable mess of 2020, but clearing that bar didn t exactly require a Fosbury flop.
More than two months into this season, however, there s no obvious candidate to kick to the bullpen. Based purely on results, it would be Eduardo Rodriguez. Based on stuff, it would be Martin Perez. Based on service time, it would be Nick Pivetta. Based on repertoire, it would be Garrett Richards. It s hard to envision any scenario in which it s a healthy Nathan Eovaldi.